New developments in the treatment of chronic hepatitis B

Expert Opinion on Biological Therapy

Volumn 6, Issue 9, 2006, Pages 913-921

  Hadziyannis, Stephanos J ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Adefovir; Chronic hepatitis B; Combination therapy; Entecavir; Interferon ; Lamivudine; Monotherapy; Viral resistance

Indexed keywords

ADEFOVIR; ADENINE; ALPHA2A INTERFERON; ANTIVIRUS AGENT; DRUG DERIVATIVE; ENTECAVIR; GUANINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A; PHOSPHONIC ACID DERIVATIVE; VIRUS DNA;

ANIMAL; ANTIBIOTIC RESISTANCE; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; HEPATITIS B; HUMAN; IMMUNOLOGY; PATIENT SELECTION; REVIEW; VIROLOGY;

ADENINE; ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; LAMIVUDINE; PATIENT SELECTION; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS;

EID: 33749054748     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.9.913     Document Type: Review

References (77)

1. MADDREY WC: Hepatitis B: an important public health issue. J. Med. Virol. (2000) 61:362-366. (Pubitemid 30368539)
2. PAPATHEODORIDIS GV, HADZIYANNIS SJ: Current management of chronic hepatitis B. Aliment. Pharmacol. Ther. (2004) 19:25-37. • A review of CHB treatment, with practical recommendations for the clinician.
3. HADZIYANNIS SJ, PAPATHEODORIDIS GV: Emerging treatments in chronic hepatitis B. Expert Opin. Emerg. Drugs (2004) 9:207-221. (Pubitemid 39627125)
4. LOK AS, HEATHCOTE EJ, HOOFNAGLE JH: Management of hepatitis B: 2000Summary of a workshop. Gastroenterology (2001) 120:1828-1853. • Summary of an international 3-day workshop sponsored by NIDDK on the management of CHB.
5. - CHB with superiority over LAM, whereas combination of PEG-IFN-α-2a with LAM did not increase efficacy.
6. KEEFE EB, DIETERICH DT, HAN SH et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin. Gastroenterol. Hepatol. (2004) 2:87-106. (Pubitemid 38180462)
7. NO AUTHORS LISTED: Proceedings of the European Association for the Study of the Liver (EASL) International consensus conference on hepatitis B. September 14-16, 2002. Geneva, Switzerland. J. Hepatol. (2003) 39(Suppl. 1):S3-S25.
8. LAU GK, PIRATVISUTH T, LUO KX et al.: Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. (2005) 352:2682-2695. (Pubitemid 41007823)
9. JANSSEN HL, VAN ZONNEVELD M, SENTURK H et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 365:123-129. (Pubitemid 40091801)
10. + patients.
11. LOK AS: The maze of treatment of hepatitis B. N. Engl. J. Med. (2005) 353:2743-2746.
12. MARCELLIN P, CHANG T, LIM S et al.: Increasing serologic, virologic and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients. J. Hepatol. (2005) 42(Suppl. 2):31-32.
13. HOOFNAGLE JH: Hepatitis B - preventable and now treatable. N. Engl. J. Med. (2006) 354:1074-1076. •• Critical and impartial comments on the treatment of CHB with newer drugs, in particular ETV.
14. - CHB.
15. - patients.
16. CHANG TT, GISH RG, HADZIYANNIS SJ et al.: A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology (2005) 129:1198-1209. (Pubitemid 41446860)
17. YURDAYDIN C, SOLLANO J, HADZIYANNIS S et al.: Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026). J. Hepatol. (2006) 44(2):S36 (Abstract).
18. LIAW YF, SUNG JJ, CHOW WC et al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. (2004) 351:1521-1531. (Pubitemid 39315319)
19. PETERS MG, HANN HH, MARTIN P et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 126:91-101. (Pubitemid 38040727)
20. - CHB is extremely effective if applied as soon as genotypic resistance to LAM develops.
21. FUNG SK, CHAE HB, FONTANA RJ et al.: Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. (2006) 44:283-290. • A study showing that resistance to adefovir in LAM-resistant patients may develop early and quite frequently if adefovir is substituting LAM rather than added to it.
22. FUNG SK, ANDREONE P, HAN SH et al.: Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. (2005) 43:937-943. (Pubitemid 41627977)
23. PAPATHEODORIDIS GV, DIMOU E, DIMAKOPOULOS K et al.: Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology (2005) 42:121-129. (Pubitemid 40911319)
24. COLONNO R, ROSE R, LEVINE S et al.: Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients. Hepatology (2005) 42(Suppl. 1):574A.
25. - CHB.
26. DI MARCO V, MARZANO A, LAMPERTICO P et al.: Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology (2004) 40:883-891. (Pubitemid 39288121)
27. LAMPERTICO P, VIGANO P, MANENTI E et al.: Five years of sequential LAM to LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma. Hepatology (2005) 42(Suppl. 1):582A.
28. - CHB, and the loss of benefit if therapy is discontinued.
29. LOCARNINI S, QI X, ARTERBURN S et al.: Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J. Hepatol. (2005) 42(Suppl. 2):17.
30. ANGUS P, VAUGHAN R, XIONG S et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 125:292-297. • The first study describing the HBV mutations associated with resistance to ADV.
31. QI X, SNOW A, THIBAULT V et al.: Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy. J. Hepatol. (2004) 40(Suppl. 1):20.
32. YANG H, QI X, DAS K et al.: In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation RTN236T in the HBV polymerase. J. Hepatol. (2004) 40(Suppl. 1):114.
33. ALOMAN C, WANDS JR: Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy? Hepatology (2003) 38:1584-1587.
34. FUNG SK, CHAE HB, FONTANA R et al.: HBV genotype D and switch to adefovir (ADV) monotherapy are associated with increased risk of ADV resistance in chronic hepatitis B (CHB) patients. Hepatology (2005) 42(Suppl. 1):590A.
35. LEE CK, YEON JE, HONG SP et al.: More frequent and earlier emergence of adefovir (ADV) resistance mutations in lamivudine resistant patients treated with ADV compared to previously reported nucleoside-treatment naive patients. Hepatology (2005) 42(Suppl. 1):593A.
36. LAMPERTICO P, MARZANO A, BATTISTA G et al.: A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: a 2-year analysis of 604 patients. Hepatology (2005) 42(Suppl. 1):591A.
37. MANOLAKOPOULOS S, BETHANIS S, KOUTSOUNAS S et al.: Adefovir alone or combination with lamivudine in patients with lamivudine-resistance chronic HBeAg-negative hepatitis B: a non-randomized multicenter controlled study. Hepatology (2005) 42(Suppl. 1):592A.
38. YUAN HJ, YUEN MF, KA-HO WD, SABLON E, LAI CL: The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J. Viral Hepat. (2005) 12:373-379. (Pubitemid 40961476)
39. MANESIS E, PAPATHEODORIDIS GV, SEVASTIANOS V et al.: Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with HBeAg-negative chronic hepatitis B virus infection. Am. J. Gastroenterol. (2003) 98:2261-2267. (Pubitemid 37305368)
40. CHU CJ, HUSSAIN M, LOK AS: Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology (2002) 36:1408-1415. (Pubitemid 35407438)
41. HOCHBERGER S, ALTHOF D, DE SCHROTT RG et al.: Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS((R)) AmpliPrep/COBAS((R)) TaqMan((R)) system. J. Clin. Virol. (2006) 35:373-380. • An important study showing the great superiority over previously used methods of an automated assay of HBV DNA quantification.
42. HADZIYANNIS AS, MITSOULA P, HADZIYANNIS E et al.: Monitoring serum HBV-DNA levels with the TaqMan technique during treatment of HBeAg(-) chronic hepatitis B with lamivudine. Hepatology (2005) 42(Suppl. 1):726A-727A (Abstract).
43. MCMAHON BJ: The natural history of chronic hepatitis B virus infection. Semin. Liver Dis. (2004) 24(Suppl. 1):17-21. (Pubitemid 38738354)
44. LIAW YF, CHU CM, SU IJ et al.: Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology (1983) 84:216-219. (Pubitemid 13224257)
45. HADZIYANNIS S, GERBER MA, VISSOULIS C, POPPER H: Cytoplasmic hepatitis B antigen in 'ground-glass' hepatocytes of carriers. Arch. Pathol. (1973) 96:327-330.
46. - CHB from the initial recognition of its existence to its epidemiology, pathogenesis, natural course and treatment.
47. BRUNETTO MR, OLIVERI F, ROCCA G et al.: Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology (1989) 10:198-202. (Pubitemid 19190211)
48. HSU YS, CHIEN RN, YEH CT et al.: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology (2002) 35:1522-1527. (Pubitemid 34966908)
49. - CHB.
50. FUNK ML, ROSENBERG DM, LOK AS: World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J. Viral Hepat. (2002) 9:52-61. (Pubitemid 36002487)
51. CHAN HL, LEUNG NW, HUSSAIN M, WONG ML, LOK AS: Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology (2000) 31:763-768. (Pubitemid 30118648)
52. LOK AS, MCMAHON BJ: Chronic hepatitis B: update of recommendations. Hepatology (2004) 39:857-861. (Pubitemid 38337668)
53. CHEN M, SALLBERG M, HUGHES J et al.: Immune tolerance split between hepatitis B virus precore and core proteins. J. Virol. (2005) 79:3016-3027. (Pubitemid 40270581)
54. HADZIYANNIS SJ, BRAMOU A, ALEXOPOULOU A, MAKRIS A: Immunopathogenesis and natural course of anti-HBe-positive chronic hepatitis with replicating B virus. In: Viral Hepatitis and Liver Disease. Hollinger FB, Lemon SM, Margolis HS (Eds), Williams & Wilkins, Baltimore, MD, USA (1991):673-676.
55. REHERMANN B, NASCIMBENI M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. (2005) 5:215-229. • An important critical review of the immunology of chronic viral hepatitis.
56. PAPATHEODORIDIS GV, MANESIS E, HADZIYANNIS SJ: The long-term outcome of interferon-a treated and untreated patients with HBeAg-negative chronic hepatitis B. J. Hepatol. (2001) 34:306-313. (Pubitemid 32176454)
57. BRUNETTO MR, OLIVERI F, COCO B et al.: Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long-term cohort study. J. Hepatol. (2002) 36:263-270. (Pubitemid 34146434)
58. CHAN HL, TSANG SW, LIEW CT et al.: Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am. J. Gastroenterol. (2002) 97:406-412. (Pubitemid 34160768)
59. LIAW YF, TSAI SL, SHEEN IS et al.: Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am. J. Gastroenterol. (1998) 93:354-359. (Pubitemid 29068336)
60. FATTOVICH G: Natural history and prognosis of hepatitis B. Semin. Liver Dis. (2003) 23:47-58. (Pubitemid 36254662)
61. HADZIYANNIS S, LAU GK, MARCELLIN P et al.: Sustaiened HBsAg seroconversion in patients with chronic hepatitis B treated with peginterferon-alfa-2a (40KD) (Pegasys). J. Hepatol. (2005) 42(2):S178 (Abstract).
62. MARCELLIN P, BONINO F, LAU GK et al.: The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40 KD) (Pegasys) sustain responses 2 years post-treatment. J. Hepatol. (2006) 44(2):S274 (Abstract). • Recent data communicated at the EASL Vienna Meeting of April 2006, indicating a high rate of sustained response to PEG-IFN-α-2a (40 kDa) 2 years after stopping treatment.
63. MARCELLIN P, BONINO F, LAU GK et al.: Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2a (40KD) (Pegasys) monotherapy for HBeAg-negative chronic hepatitis B. Hepatology (2005) 42(Suppl. 1):580A.
64. TASSOPOULOS NC, VOLPES R, PASTORE G et al.: Efficacy of lamivudine in patients with hepatitis B eantigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology (1999) 29:889-896. (Pubitemid 29109606)
65. HADZIYANNIS SJ, PAPATHEODORIDIS GV, DIMOU E, LARAS A, PAPAIOANNOU C: Efficacy of long-term lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B. Hepatology (2000) 32:847-851. (Pubitemid 30744286)
66. PAPATHEODORIDIS GV, DIMOU E, LARAS A, PAPADIMITROPOULOS V, HADZIYANNIS SJ: Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology (2002) 36:219-226. (Pubitemid 34700781)
67. FUNG SK, WONG F, HUSSAIN M, LOK AS: Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J. Viral Hepat. (2004) 11:432-438. (Pubitemid 39336224)
68. GAIA S, MARZANO A, SMEDILE A et al.: Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment. Pharmacol. Ther. (2004) 20:281-287. (Pubitemid 39062130)
69. HADZIYANNIS SJ: Treatment options for chronic hepatitis B not responding to interferon. J. Hepatol. (2003) 38:853-855. (Pubitemid 36613355)
70. TENNEY DJ, LEVINE SM, ROSE RE et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. (2004) 48:3498-3507. (Pubitemid 39129351)
71. SHAW T, LOCARNINI S: Entecavir for the treatment of chronic hepatitis B. Expert Rev. Anti Infect. Ther. (2004) 2:853-871. (Pubitemid 39591919)
72. SHAW T, BOWDEN S, LOCARNINI S: Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? Gastroenterology (2004) 126:343-347. • An important commentary editorial on the importance of combination therapy in CHB.
73. PALLIER C, CASTERA L, SOULIER A et al.: Dynamics of hepatitis B virus resistance to lamivudine. J. Virol. (2006) 80:643-653. • Important article on the dynamics of HBV resistance to LAM.
74. + CHB.
75. BORROTO-ESODA K, ANTERBURN S, SNOW A et al.: Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil (ADV) monotherapy in HBeAg-negative patients. J. Hepatol. (2006) 44(2):S179 (Abstract).
76. WESTLAND CE, YANG H, NAMIMI H et al.: Comparison of anti-HBV activity of adefovir against different lamivudine-resistant HBV strains in vitro and in liver transplant patients. Hepatology (2001) 34:446A.
77. HANN WH, CHAE HB, DUM SR et al.: Tenofovir (TNV) has stronger antiviral effect than adefovir dipovoxil (ADV) against lamivudine (LAM) resistant hepatitis B virus (HBV). J. Hepatol. (2006) 44(2):S184 (Abstract).